Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIGIN 3: Atacicept in IgA Nephropathy
jRCT2031230629Phase 3Active, not recruiting
- Sponsor
- Vera Therapeutics
- Start
- May 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Atacicept arm with Placebo arm (2 arms). Primary endpoint: Annualized rate of change in eGFR (total slope). Started May 2024; status: active, not recruiting.
02
Drugs
atacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on jRCT2031230629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230629.